FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169642435> ?p ?o ?g. }

• W3169642435 endingPage "698" @default.
• W3169642435 startingPage "698" @default.
• W3169642435 abstract "Background: The objective of this study was to investigate the efficacy and safety of early administration of oral corticosteroids (OC) or nasal corticosteroids (NC) as an add-on to olfactory training (OT) versus OT alone in patients with olfactory dysfunction (OD) related to coronavirus disease 2019 (COVID-19). Methods: Patients with a positive diagnosis of COVID-19 and OD were prospectively recruited from March 22 to December 15, 2020 from 4 European hospitals. Patients had confirmed OD on psychophysical testing. All patients undertook OT, with add-on 10 days of OC (group 1: OC + OT), or 1 month of NC (group 2: NC + OT) or olfactory training alone (group 3: OT). Olfactory evaluations (Sniffin’Sticks tests) were carried out at the time of inclusion, 1 and 2 months after the start of the therapeutic course. Results: A total of 152 hyposmic or anosmic patients completed the study. Group 1, 2 and 3 included 59, 22 and 71 patients, respectively and all patient groups were comparable regarding baseline Sniffin’Sticks tests. The median Sniffin’Sticks test values significantly improved from pre- to post-intervention in all groups. The increase of Sniffin’Sticks test values was higher in group 1 (OC + OT) compared with groups 2 and 3 (p < 0.001) at one month after treatment but did not remain so at 2 months. Groups 1, 2 and 3, respectively, presented parosmia in 20/71 (28.2%), 9/22 (40.9%) and 42/71 (59.2%) patients. This difference was statistically significant between group 1 and 3 (p < 0.001). There were no patients with a worsening of the disease or an increase of the severity of the COVID-19 symptoms. Conclusions: The use of OCs in patients with OD related to mild COVID-19 is generally well-tolerated without any case of deterioration of symptoms. OC is associated with greater improvement in psychophysical olfactory evaluations at 1-month post-treatment but there was no difference at 2 months. Parosmia may be reduced following treatment with OC and NC. On the basis of these preliminary results, it is possible to state that considering the 2 months efficacy of OC and NC with respect to the OT alone and the risk-benefit ratio, the benefit to start a specific treatment of COVID-19 related OD cannot be demonstrated and there is a need for a randomised controlled trial to assess this further." @default.
• W3169642435 created "2021-06-22" @default.
• W3169642435 creator A5008760203 @default.
• W3169642435 creator A5010086159 @default.
• W3169642435 creator A5023718451 @default.
• W3169642435 creator A5028425853 @default.
• W3169642435 creator A5036201540 @default.
• W3169642435 creator A5037796306 @default.
• W3169642435 creator A5043488060 @default.
• W3169642435 creator A5054650261 @default.
• W3169642435 creator A5060829576 @default.
• W3169642435 creator A5069830932 @default.
• W3169642435 creator A5070163206 @default.
• W3169642435 creator A5084313111 @default.
• W3169642435 creator A5085883942 @default.
• W3169642435 creator A5088288285 @default.
• W3169642435 date "2021-06-04" @default.
• W3169642435 modified "2023-10-06" @default.
• W3169642435 title "Short-Term Efficacy and Safety of Oral and Nasal Corticosteroids in COVID-19 Patients with Olfactory Dysfunction: A European Multicenter Study" @default.
• W3169642435 cites W1497897461 @default.
• W3169642435 cites W2069406660 @default.
• W3169642435 cites W2094866624 @default.
• W3169642435 cites W2288587225 @default.
• W3169642435 cites W2579454308 @default.
• W3169642435 cites W2903978256 @default.
• W3169642435 cites W2998494626 @default.
• W3169642435 cites W3022635068 @default.
• W3169642435 cites W3026644851 @default.
• W3169642435 cites W3027667132 @default.
• W3169642435 cites W3034281578 @default.
• W3169642435 cites W3036378829 @default.
• W3169642435 cites W3038036199 @default.
• W3169642435 cites W3040417141 @default.
• W3169642435 cites W3041589472 @default.
• W3169642435 cites W3045867311 @default.
• W3169642435 cites W3046540101 @default.
• W3169642435 cites W3047554984 @default.
• W3169642435 cites W3080391729 @default.
• W3169642435 cites W3092775354 @default.
• W3169642435 cites W3093322093 @default.
• W3169642435 cites W3106260565 @default.
• W3169642435 cites W3106659977 @default.
• W3169642435 cites W3110236540 @default.
• W3169642435 cites W3112490366 @default.
• W3169642435 cites W3118739000 @default.
• W3169642435 cites W3119614191 @default.
• W3169642435 cites W3119632436 @default.
• W3169642435 cites W3120583068 @default.
• W3169642435 cites W3128785414 @default.
• W3169642435 cites W3136838263 @default.
• W3169642435 cites W3136935895 @default.
• W3169642435 cites W3145623002 @default.
• W3169642435 cites W3149671729 @default.
• W3169642435 cites W3153458752 @default.
• W3169642435 cites W3158546585 @default.
• W3169642435 cites W4254603555 @default.
• W3169642435 doi "https://doi.org/10.3390/pathogens10060698" @default.
• W3169642435 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8228154" @default.
• W3169642435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34199734" @default.
• W3169642435 hasPublicationYear "2021" @default.
• W3169642435 type Work @default.
• W3169642435 sameAs 3169642435 @default.
• W3169642435 citedByCount "31" @default.
• W3169642435 countsByYear W31696424352021 @default.
• W3169642435 countsByYear W31696424352022 @default.
• W3169642435 countsByYear W31696424352023 @default.
• W3169642435 crossrefType "journal-article" @default.
• W3169642435 hasAuthorship W3169642435A5008760203 @default.
• W3169642435 hasAuthorship W3169642435A5010086159 @default.
• W3169642435 hasAuthorship W3169642435A5023718451 @default.
• W3169642435 hasAuthorship W3169642435A5028425853 @default.
• W3169642435 hasAuthorship W3169642435A5036201540 @default.
• W3169642435 hasAuthorship W3169642435A5037796306 @default.
• W3169642435 hasAuthorship W3169642435A5043488060 @default.
• W3169642435 hasAuthorship W3169642435A5054650261 @default.
• W3169642435 hasAuthorship W3169642435A5060829576 @default.
• W3169642435 hasAuthorship W3169642435A5069830932 @default.
• W3169642435 hasAuthorship W3169642435A5070163206 @default.
• W3169642435 hasAuthorship W3169642435A5084313111 @default.
• W3169642435 hasAuthorship W3169642435A5085883942 @default.
• W3169642435 hasAuthorship W3169642435A5088288285 @default.
• W3169642435 hasBestOaLocation W31696424351 @default.
• W3169642435 hasConcept C126322002 @default.
• W3169642435 hasConcept C197934379 @default.
• W3169642435 hasConcept C2776804153 @default.
• W3169642435 hasConcept C2779134260 @default.
• W3169642435 hasConcept C2781348165 @default.
• W3169642435 hasConcept C3008058167 @default.
• W3169642435 hasConcept C3018023364 @default.
• W3169642435 hasConcept C524204448 @default.
• W3169642435 hasConcept C71924100 @default.
• W3169642435 hasConcept C85663871 @default.
• W3169642435 hasConcept C90924648 @default.
• W3169642435 hasConcept C98274493 @default.
• W3169642435 hasConceptScore W3169642435C126322002 @default.
• W3169642435 hasConceptScore W3169642435C197934379 @default.
• W3169642435 hasConceptScore W3169642435C2776804153 @default.
• W3169642435 hasConceptScore W3169642435C2779134260 @default.

• next